CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Accounts Receivable, Allowance for Credit Loss, Writeoff
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $2.87 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-06-27 was $476.00K, a 86.79% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2026-03-28 was $2.40M, a 40.84% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-12-27 was $4.84M, a 60.05% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2025-09-27 was $1.40M, a 69.40% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2025 was $13.90M, a 37.37% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2024 was $22.20M, a 487.01% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2023 was $3.78M, a 44.98% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2022 was $2.61M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 6 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 9 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2026-06-27 | $476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.87M 10-Q · filed 2026-08-05 | $7.72M derived: sum of 3 quarters · filed 2026-08-05 | $9.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $2.40M 10-Q · filed 2026-05-07 | $7.24M derived: sum of 2 quarters · filed 2026-05-07 | $8.64M derived: sum of 3 quarters · filed 2026-05-07 | $12.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $6.25M derived: sum of 2 quarters · filed 2026-02-18 | $9.85M derived: sum of 3 quarters · filed 2026-08-05 | $13.90M 10-K · filed 2026-02-18 |
| 2025-09-27 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.00M derived: sum of 2 quarters · filed 2026-08-05 | $9.05M 10-Q · filed 2025-11-05 | $21.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.65M 10-Q · filed 2026-08-05 | $19.78M derived: sum of 3 quarters · filed 2026-08-05 | $24.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $4.05M 10-Q · filed 2026-05-07 | $16.18M derived: sum of 2 quarters · filed 2026-05-07 | $20.75M derived: sum of 3 quarters · filed 2026-05-07 | $25.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $16.70M derived: sum of 2 quarters · filed 2026-02-18 | $20.95M derived: sum of 3 quarters · filed 2026-02-18 | $22.20M 10-K · filed 2026-02-18 |
| 2024-09-28 | $4.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.82M derived: sum of 2 quarters · filed 2025-11-05 | $10.07M 10-Q · filed 2025-11-05 | $12.73M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.49M 10-Q · filed 2025-08-06 | $8.15M derived: sum of 3 quarters · filed 2026-02-18 | $6.18M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $1.25M 10-Q · filed 2025-05-07 | $3.91M derived: sum of 2 quarters · filed 2026-02-18 | $1.94M derived: sum of 3 quarters · filed 2026-02-18 | $4.71M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $694.00K derived: sum of 2 quarters · filed 2026-02-18 | $3.47M derived: sum of 3 quarters · filed 2026-02-18 | $3.78M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $806.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.12M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.09M 10-Q · filed 2024-08-07 | ||
| 2023-04-01 | $315.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $2.61M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |